Thursday, January 4, 2007 7:30:00 AM PDT | VentureDeal Staff
NATICK, MA -- Boston Scientific Corporation (NYSE: BSX) announced that it had acquired EndoTex Interventional Systems, following the FDA approval of EndoTex' NexStent (R) Carotid Stent System that was studied in a trial with Boston Scientifics FilterWire Embolic Protection System. The NexStent system is a "laser-cut, nitinol stent with rolled sheet design that enables one stent size to adapt to multiple diameters in tapered or non-tapered vessel systems." Terms of the transaction were not disclosed.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
